Search the GHTC website

Global health R&D delivers for Oregon

US government investment in global health R&D has delivered

Amount
$98.4 million
to Oregon research institutions
Jobs
1,300+ new jobs
for Oregon
Oregon's top USG-funded global health R&D institutions

Oregon's top USG-funded global health R&D institutions

Oregon Health and Science University
$84.7 million
Portland State University
$7.1 million
Oregon State University
$6.2 million
University of Oregon
$289 thousand
Oregon industry in global health R&D

Oregon industry in global health R&D

DesignMedix
Location(s): Portland
Hemax Health
Location(s): Portland
mAbDx
Location(s): Eugene
Najit Technologies
Location(s): Beaverton
Sedia Biosciences Corporation
Location(s): Portland
SIGA Technologies
Location(s): Corvallis
Viti
Location(s): Portland

Oregon's top areas of global health R&D by USG funding

40.1%
HIV/AIDS
10%
Malaria
23.5%
Tuberculosis
3.7%
Diarrheal diseases
2.6%
Salmonella infections
19.3%
Neglected tropical diseases
Dengue
Helminths
Kinetoplastids
1%
Other
Global health R&D at work in Oregon

Portland State University (PSU) researchers have revived a once-potent malaria drug and created a company to move it forward. For many years, chloroquine was considered a miracle drug in treating malaria until the disease developed resistance. Rather than abandon it, PSU scientists reversed the resistance process with chemicals. This work led to a group of chloroquine hybrids and the birth of DesignMedix, a Portland start-up specializing in new approaches to fight infectious diseases. With funding from investors, the company provides opportunities for students and jobs for the region, highlighting the economic benefits of global health R&D.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: PATH/Patrick McKern